| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 36 | 2024 | 372 | 5.700 |
Why?
|
| Barrett Esophagus | 29 | 2024 | 340 | 4.700 |
Why?
|
| Esophagoscopy | 24 | 2024 | 155 | 4.340 |
Why?
|
| Optical Imaging | 10 | 2020 | 67 | 3.350 |
Why?
|
| Precancerous Conditions | 12 | 2020 | 282 | 2.840 |
Why?
|
| Adenocarcinoma | 21 | 2022 | 1023 | 2.140 |
Why?
|
| Esophagus | 12 | 2020 | 214 | 2.070 |
Why?
|
| Colonoscopy | 8 | 2018 | 236 | 1.990 |
Why?
|
| Microscopy | 10 | 2024 | 119 | 1.780 |
Why?
|
| Colorectal Neoplasms | 9 | 2019 | 576 | 1.760 |
Why?
|
| Endoscopy, Gastrointestinal | 8 | 2020 | 241 | 1.680 |
Why?
|
| Endoscopy | 8 | 2024 | 279 | 1.600 |
Why?
|
| Early Detection of Cancer | 10 | 2024 | 360 | 1.450 |
Why?
|
| Colonic Neoplasms | 3 | 2019 | 248 | 1.190 |
Why?
|
| Image Enhancement | 9 | 2015 | 163 | 1.130 |
Why?
|
| Colonic Polyps | 4 | 2018 | 78 | 1.050 |
Why?
|
| Gastrointestinal Neoplasms | 4 | 2020 | 80 | 0.940 |
Why?
|
| Adenoma | 3 | 2015 | 129 | 0.910 |
Why?
|
| Microscopy, Confocal | 12 | 2019 | 348 | 0.900 |
Why?
|
| Gastroenterology | 4 | 2021 | 196 | 0.820 |
Why?
|
| Internationality | 2 | 2021 | 130 | 0.820 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2024 | 673 | 0.810 |
Why?
|
| Sensitivity and Specificity | 15 | 2020 | 2043 | 0.770 |
Why?
|
| Physicians, Women | 2 | 2021 | 47 | 0.760 |
Why?
|
| Developing Countries | 1 | 2024 | 265 | 0.760 |
Why?
|
| Biopsy | 9 | 2024 | 1234 | 0.750 |
Why?
|
| Microscopy, Fluorescence | 4 | 2015 | 329 | 0.710 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2018 | 221 | 0.670 |
Why?
|
| Orthomyxoviridae | 1 | 2019 | 51 | 0.620 |
Why?
|
| Laboratories | 1 | 2019 | 82 | 0.600 |
Why?
|
| Neoplasms | 3 | 2024 | 2780 | 0.600 |
Why?
|
| Molecular Imaging | 3 | 2013 | 63 | 0.590 |
Why?
|
| Physician's Role | 2 | 2021 | 166 | 0.580 |
Why?
|
| Humans | 78 | 2024 | 124705 | 0.570 |
Why?
|
| Carcinoma in Situ | 1 | 2018 | 71 | 0.570 |
Why?
|
| Intestinal Polyps | 2 | 2015 | 29 | 0.550 |
Why?
|
| Gastroesophageal Reflux | 3 | 2009 | 295 | 0.520 |
Why?
|
| Laser Therapy | 2 | 2009 | 249 | 0.510 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2015 | 8 | 0.490 |
Why?
|
| Gastroscopy | 2 | 2013 | 100 | 0.480 |
Why?
|
| Endoscopes | 4 | 2019 | 20 | 0.480 |
Why?
|
| Mucous Membrane | 3 | 2012 | 90 | 0.470 |
Why?
|
| Societies, Medical | 1 | 2018 | 691 | 0.460 |
Why?
|
| China | 5 | 2024 | 245 | 0.450 |
Why?
|
| Proctoscopy | 1 | 2013 | 6 | 0.440 |
Why?
|
| Population Surveillance | 1 | 2016 | 386 | 0.440 |
Why?
|
| Adenomatous Polyps | 1 | 2013 | 13 | 0.420 |
Why?
|
| Anus Neoplasms | 2 | 2023 | 38 | 0.420 |
Why?
|
| Influenza, Human | 1 | 2019 | 656 | 0.400 |
Why?
|
| Rectal Neoplasms | 1 | 2013 | 79 | 0.400 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2015 | 618 | 0.400 |
Why?
|
| Health Care Costs | 1 | 2015 | 369 | 0.390 |
Why?
|
| Cryosurgery | 1 | 2012 | 47 | 0.380 |
Why?
|
| Endosonography | 3 | 2019 | 79 | 0.370 |
Why?
|
| Gastroenterologists | 2 | 2021 | 11 | 0.370 |
Why?
|
| Stomach | 1 | 2013 | 272 | 0.350 |
Why?
|
| Colitis, Ulcerative | 2 | 2012 | 205 | 0.340 |
Why?
|
| Lasers, Gas | 1 | 2009 | 7 | 0.320 |
Why?
|
| Middle Aged | 21 | 2024 | 26884 | 0.310 |
Why?
|
| Myocarditis | 2 | 2002 | 129 | 0.310 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2008 | 86 | 0.310 |
Why?
|
| Iodides | 3 | 2024 | 15 | 0.300 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2022 | 68 | 0.300 |
Why?
|
| Fluorescent Dyes | 5 | 2013 | 262 | 0.300 |
Why?
|
| Fiber Optic Technology | 5 | 2024 | 46 | 0.290 |
Why?
|
| Autoimmune Diseases | 2 | 2002 | 249 | 0.290 |
Why?
|
| Tomography, Optical Coherence | 6 | 2013 | 522 | 0.280 |
Why?
|
| Catheter Ablation | 2 | 2022 | 233 | 0.270 |
Why?
|
| Esophageal pH Monitoring | 1 | 2006 | 3 | 0.270 |
Why?
|
| Hernia, Hiatal | 1 | 2007 | 55 | 0.270 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2024 | 584 | 0.260 |
Why?
|
| Aged, 80 and over | 8 | 2015 | 6584 | 0.260 |
Why?
|
| Electric Impedance | 1 | 2006 | 59 | 0.260 |
Why?
|
| HIV Infections | 3 | 2023 | 1878 | 0.250 |
Why?
|
| Coloring Agents | 3 | 2024 | 77 | 0.250 |
Why?
|
| Female | 27 | 2024 | 66577 | 0.250 |
Why?
|
| Male | 25 | 2024 | 61317 | 0.240 |
Why?
|
| Aged | 13 | 2024 | 19830 | 0.230 |
Why?
|
| Deglutition Disorders | 1 | 2006 | 131 | 0.230 |
Why?
|
| Methylene Blue | 1 | 2024 | 13 | 0.230 |
Why?
|
| Observer Variation | 3 | 2013 | 299 | 0.220 |
Why?
|
| Neoplasm Staging | 5 | 2019 | 1278 | 0.210 |
Why?
|
| Predictive Value of Tests | 4 | 2024 | 2161 | 0.210 |
Why?
|
| Equipment Design | 5 | 2024 | 598 | 0.210 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 1873 | 0.210 |
Why?
|
| Body Mass Index | 1 | 2009 | 1562 | 0.200 |
Why?
|
| Career Choice | 2 | 2021 | 146 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 350 | 0.200 |
Why?
|
| Diagnostic Imaging | 3 | 2023 | 277 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 124 | 0.190 |
Why?
|
| Women, Working | 1 | 2021 | 9 | 0.190 |
Why?
|
| Metaplasia | 6 | 2022 | 213 | 0.180 |
Why?
|
| Algorithms | 5 | 2018 | 1625 | 0.180 |
Why?
|
| Colonoscopes | 2 | 2013 | 10 | 0.180 |
Why?
|
| Prospective Studies | 6 | 2015 | 6132 | 0.180 |
Why?
|
| Stomach Neoplasms | 2 | 2019 | 546 | 0.180 |
Why?
|
| Job Satisfaction | 1 | 2021 | 79 | 0.170 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2002 | 213 | 0.170 |
Why?
|
| Pancreas | 2 | 2012 | 219 | 0.170 |
Why?
|
| Software | 2 | 2024 | 683 | 0.160 |
Why?
|
| Kenya | 1 | 2019 | 52 | 0.160 |
Why?
|
| Virus Diseases | 1 | 2002 | 280 | 0.160 |
Why?
|
| Intravital Microscopy | 2 | 2016 | 16 | 0.160 |
Why?
|
| United States | 6 | 2024 | 10866 | 0.160 |
Why?
|
| Global Health | 1 | 2024 | 554 | 0.160 |
Why?
|
| Robotics | 2 | 2024 | 108 | 0.160 |
Why?
|
| Carbon Dioxide | 2 | 2012 | 278 | 0.160 |
Why?
|
| Pilot Projects | 4 | 2016 | 1396 | 0.160 |
Why?
|
| Mass Screening | 3 | 2019 | 772 | 0.150 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 162 | 0.150 |
Why?
|
| Virtual Reality | 1 | 2018 | 28 | 0.150 |
Why?
|
| Prognosis | 4 | 2015 | 4620 | 0.150 |
Why?
|
| Preceptorship | 1 | 2018 | 32 | 0.150 |
Why?
|
| Chemoprevention | 2 | 2016 | 58 | 0.150 |
Why?
|
| Adult | 12 | 2024 | 29554 | 0.140 |
Why?
|
| Feasibility Studies | 5 | 2015 | 759 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 846 | 0.140 |
Why?
|
| Esophagectomy | 2 | 2016 | 64 | 0.140 |
Why?
|
| Obesity | 1 | 2009 | 2248 | 0.140 |
Why?
|
| Manikins | 1 | 2018 | 135 | 0.140 |
Why?
|
| Swine | 3 | 2012 | 1210 | 0.140 |
Why?
|
| Forecasting | 1 | 2018 | 352 | 0.140 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 503 | 0.140 |
Why?
|
| Teaching | 1 | 2018 | 189 | 0.130 |
Why?
|
| Models, Animal | 2 | 2009 | 465 | 0.130 |
Why?
|
| Computers, Handheld | 1 | 2016 | 33 | 0.120 |
Why?
|
| Epithelial Cells | 1 | 2020 | 909 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2019 | 4799 | 0.120 |
Why?
|
| Proflavine | 2 | 2012 | 2 | 0.120 |
Why?
|
| Capsule Endoscopes | 1 | 2015 | 1 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 660 | 0.120 |
Why?
|
| Models, Economic | 1 | 2015 | 51 | 0.120 |
Why?
|
| Colon | 2 | 2018 | 349 | 0.120 |
Why?
|
| Proton Pump Inhibitors | 2 | 2009 | 258 | 0.120 |
Why?
|
| Video Recording | 2 | 2013 | 183 | 0.120 |
Why?
|
| Markov Chains | 1 | 2015 | 83 | 0.120 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 110 | 0.120 |
Why?
|
| Reproducibility of Results | 4 | 2015 | 2885 | 0.110 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2015 | 60 | 0.110 |
Why?
|
| Proctoscopes | 1 | 2013 | 2 | 0.110 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 68 | 0.110 |
Why?
|
| Contrast Media | 3 | 2011 | 479 | 0.100 |
Why?
|
| Risk Factors | 4 | 2019 | 10249 | 0.100 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2015 | 165 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2022 | 16263 | 0.100 |
Why?
|
| Hyperplasia | 1 | 2013 | 208 | 0.100 |
Why?
|
| Rectum | 1 | 2013 | 100 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 505 | 0.100 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2012 | 28 | 0.100 |
Why?
|
| Animals | 7 | 2024 | 34235 | 0.100 |
Why?
|
| Optical Fibers | 2 | 2024 | 18 | 0.100 |
Why?
|
| 4-Chloro-7-nitrobenzofurazan | 1 | 2011 | 3 | 0.100 |
Why?
|
| Deoxyglucose | 1 | 2011 | 33 | 0.090 |
Why?
|
| Intestinal Mucosa | 2 | 2013 | 778 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2019 | 3444 | 0.090 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 216 | 0.090 |
Why?
|
| Surgical Instruments | 1 | 2010 | 56 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2009 | 3293 | 0.090 |
Why?
|
| Adrenergic Antagonists | 2 | 2002 | 4 | 0.090 |
Why?
|
| Light | 1 | 2010 | 176 | 0.080 |
Why?
|
| Calcium Channel Blockers | 2 | 2002 | 115 | 0.080 |
Why?
|
| Career Mobility | 2 | 2021 | 50 | 0.080 |
Why?
|
| Pattern Recognition, Automated | 1 | 2010 | 49 | 0.080 |
Why?
|
| Mobile Applications | 2 | 2024 | 89 | 0.080 |
Why?
|
| Needles | 1 | 2009 | 51 | 0.080 |
Why?
|
| Administration, Topical | 2 | 2024 | 137 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 2 | 2012 | 691 | 0.080 |
Why?
|
| Time Factors | 2 | 2019 | 6323 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2009 | 115 | 0.080 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 124 | 0.080 |
Why?
|
| ROC Curve | 3 | 2017 | 568 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 139 | 0.080 |
Why?
|
| Age Factors | 1 | 2015 | 2807 | 0.080 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2008 | 34 | 0.070 |
Why?
|
| Incidence | 2 | 2009 | 3115 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3415 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2009 | 303 | 0.070 |
Why?
|
| Age Distribution | 1 | 2009 | 414 | 0.070 |
Why?
|
| Pregnancy Complications | 2 | 2024 | 512 | 0.070 |
Why?
|
| Spectrum Analysis | 1 | 2008 | 65 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 231 | 0.070 |
Why?
|
| Endoscopy, Digestive System | 1 | 2008 | 149 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2012 | 504 | 0.070 |
Why?
|
| Comorbidity | 2 | 2009 | 1530 | 0.070 |
Why?
|
| Heartburn | 1 | 2006 | 15 | 0.070 |
Why?
|
| Sex Factors | 2 | 2021 | 1287 | 0.060 |
Why?
|
| Immunosuppressive Agents | 2 | 2002 | 650 | 0.060 |
Why?
|
| Omeprazole | 1 | 2006 | 97 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2006 | 427 | 0.060 |
Why?
|
| Quality of Life | 1 | 2015 | 1936 | 0.060 |
Why?
|
| Liver | 1 | 2012 | 1742 | 0.060 |
Why?
|
| Mice | 3 | 2016 | 17645 | 0.060 |
Why?
|
| Gambia | 1 | 2024 | 28 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1694 | 0.060 |
Why?
|
| Smartphone | 1 | 2024 | 37 | 0.060 |
Why?
|
| Printing, Three-Dimensional | 1 | 2024 | 69 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 579 | 0.050 |
Why?
|
| Obstetric Labor Complications | 1 | 2024 | 93 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 3715 | 0.050 |
Why?
|
| Anal Canal | 1 | 2023 | 82 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2013 | 237 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 1260 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2009 | 838 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2022 | 12364 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 1290 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2024 | 173 | 0.050 |
Why?
|
| Parental Leave | 1 | 2021 | 4 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2024 | 678 | 0.050 |
Why?
|
| Logistic Models | 1 | 2006 | 1807 | 0.050 |
Why?
|
| Prenatal Care | 1 | 2024 | 347 | 0.050 |
Why?
|
| Disease Progression | 3 | 2016 | 2057 | 0.040 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2021 | 70 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2021 | 42 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 2900 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 224 | 0.040 |
Why?
|
| Pregnancy | 2 | 2024 | 7171 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2021 | 127 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2021 | 142 | 0.040 |
Why?
|
| Fungal Vaccines | 1 | 1999 | 1 | 0.040 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1999 | 11 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 1002 | 0.040 |
Why?
|
| Antibodies, Fungal | 1 | 1999 | 13 | 0.040 |
Why?
|
| Cryptococcus neoformans | 1 | 1999 | 20 | 0.040 |
Why?
|
| Mentors | 1 | 2021 | 148 | 0.040 |
Why?
|
| Tetanus Toxoid | 1 | 1999 | 45 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 28 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 5154 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 1492 | 0.040 |
Why?
|
| Watchful Waiting | 1 | 2019 | 70 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 231 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2024 | 605 | 0.040 |
Why?
|
| Polysaccharides | 1 | 1999 | 140 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 1159 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2002 | 1504 | 0.040 |
Why?
|
| Autoimmunity | 1 | 1999 | 172 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 279 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 1998 | 120 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 778 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 1113 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 243 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2019 | 343 | 0.030 |
Why?
|
| Africa, Western | 1 | 2016 | 12 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 515 | 0.030 |
Why?
|
| Education, Nursing | 1 | 2016 | 12 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 1998 | 383 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1998 | 306 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2008 | 1052 | 0.030 |
Why?
|
| Neck Dissection | 1 | 2015 | 18 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1357 | 0.030 |
Why?
|
| Emergency Treatment | 1 | 2016 | 84 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 763 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2015 | 85 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 1238 | 0.030 |
Why?
|
| Young Adult | 2 | 2024 | 9023 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 1998 | 492 | 0.030 |
Why?
|
| Mouth | 1 | 2015 | 62 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2016 | 227 | 0.030 |
Why?
|
| Smoking | 1 | 2019 | 1047 | 0.030 |
Why?
|
| Narrow Band Imaging | 1 | 2013 | 2 | 0.030 |
Why?
|
| Interferometry | 1 | 2013 | 26 | 0.030 |
Why?
|
| Optical Phenomena | 1 | 2013 | 10 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 1998 | 750 | 0.030 |
Why?
|
| Learning Curve | 1 | 2012 | 53 | 0.020 |
Why?
|
| Education, Medical | 1 | 2016 | 288 | 0.020 |
Why?
|
| Fluorescence | 1 | 2012 | 96 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 4396 | 0.020 |
Why?
|
| Hospitals | 1 | 2014 | 386 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 154 | 0.020 |
Why?
|
| Color | 1 | 2010 | 31 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2012 | 979 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 314 | 0.020 |
Why?
|
| Adolescent | 2 | 2024 | 19221 | 0.020 |
Why?
|
| Goblet Cells | 1 | 2011 | 103 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2010 | 187 | 0.020 |
Why?
|
| Helicobacter pylori | 1 | 2019 | 1320 | 0.020 |
Why?
|
| Calgranulin B | 1 | 2009 | 9 | 0.020 |
Why?
|
| Keratin-5 | 1 | 2009 | 9 | 0.020 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2009 | 19 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2016 | 997 | 0.020 |
Why?
|
| Crohn Disease | 1 | 2012 | 283 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 656 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2008 | 135 | 0.020 |
Why?
|
| Veterans | 1 | 2019 | 1749 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2009 | 380 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 620 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2007 | 112 | 0.020 |
Why?
|
| Carcinoma | 1 | 2009 | 287 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2007 | 181 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 898 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 1291 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2007 | 460 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2009 | 2821 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1999 | 115 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1999 | 52 | 0.010 |
Why?
|
| Vaccines, Conjugate | 1 | 1999 | 78 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1999 | 309 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 1695 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1999 | 462 | 0.010 |
Why?
|
| Rabbits | 1 | 1999 | 717 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1999 | 192 | 0.010 |
Why?
|
| Base Sequence | 1 | 1999 | 3101 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2007 | 4534 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1999 | 3891 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1999 | 1032 | 0.010 |
Why?
|